Q-omics provides the consensus-scored PDXDC2P profile across patient tissues and cancer cell-line models. PDXDC2P expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, PDXDC2P is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, PDXDC2P RNA expression shows 16,454 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LGG, THCA, and UVM as cancer lineages where PDXDC2P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDXDC2P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDXDC2P survival associations across molecular data types. PDXDC2P RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDXDC2P RNA expression–survival associations across cancer types. High PDXDC2P expression shows unfavorable associations in LGG, LUSC and MESO, but favorable associations in LAML, READ and LUAD. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for PDXDC2P RNA expression.
This table summarizes PDXDC2P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for PDXDC2P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDXDC2P shows lower tumor expression in THCA and COAD and higher tumor expression in BRCA, BLCA, LIHC and PRAD. The THCA box plot shows higher PDXDC2P RNA expression in normal versus tumor tissue (log2 FC = −0.132, t-test p < 0.001).
This table shows molecular features associated with PDXDC2P in patient tissues and cancer cell lines. In patient samples, PDXDC2P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
